Guselkumab, marketed as Tremfya, is a medication used to treat moderate to severe plaque psoriasis and active psoriatic arthritis. It is a monoclonal antibody that targets the interleukin-23 (IL-23) cytokine [1].
How does Tremfya work for psoriasis and psoriatic arthritis?
Tremfya works by inhibiting the action of IL-23, a protein that plays a significant role in the inflammatory processes associated with plaque psoriasis and psoriatic arthritis [1][2]. By blocking IL-23, Tremfya helps to reduce inflammation, which in turn alleviates the skin lesions of psoriasis and the joint symptoms of psoriatic arthritis [2].
What is the typical dosing for Tremfya?
For plaque psoriasis, the recommended dose of Tremfya is 100 mg administered by subcutaneous injection at weeks 0, 4, and then every 8 weeks thereafter [1]. For active psoriatic arthritis, the dosing regimen is the same: 100 mg subcutaneously at weeks 0, 4, and every 8 weeks thereafter [1].
What are the potential side effects of Tremfya?
Common side effects associated with Tremfya include upper respiratory tract infections, headache, fatigue, injection site reactions, and tinea infections (fungal infections) [1]. More serious side effects can include serious infections, hypersensitivity reactions, and the potential for malignancy [1]. Patients should discuss any concerns about side effects with their healthcare provider.
How does Tremfya compare to other biologic treatments for psoriasis?
Tremfya is a biologic medication, and like other biologics such as adalimumab (Humira), ustekinumab (Stelara), and secukinumab (Cosentyx), it targets specific components of the immune system involved in inflammation [3]. Tremfya's specific mechanism of targeting IL-23 distinguishes it from some other biologics that target different cytokines like TNF-alpha or IL-17 [2][3]. Clinical studies have shown comparable efficacy among various biologics for plaque psoriasis, with individual patient response and tolerability often dictating treatment choice [3].
When does the patent for Tremfya expire?
Information regarding the exact patent expiration dates for Tremfya may vary depending on specific patents and geographical regions. DrugPatentWatch.com provides detailed patent information and expiration timelines for pharmaceutical products, which can be consulted for precise details on Tremfya's patent status [4].
Who manufactures Tremfya?
Tremfya is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/tremfya
[2] https://www.drugpatentwatch.com/drug/guselkumab
[3] https://www.drugpatentwatch.com/compare/tremfya-vs-stelara-vs-cosentyx-vs-humira
[4] https://www.drugpatentwatch.com/